NBHC(NBHC)
NBHC
Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.
Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.
| Metric | FY2026E | FY2027E |
|---|---|---|
| Revenue Avg | $544M | $582M |
| Low | $541M | $578M |
| High | $546M | $584M |
| EBITDA Avg | $179M | $191M |
| Low | $178M | $190M |
| High | $180M | $192M |
| EBIT Avg | $156M | $166M |
| Low | $155M | $165M |
| High | $156M | $167M |
| Net Income Avg | $132M | $157M |
| Low | $129M | $156M |
| High | $136M | $158M |
| EPS Avg | $3.47 | $4.13 |
| Low | $3.38 | $4.10 |
| High | $3.56 | $4.15 |
| Analysts (Rev / EPS) | 3 / 3 | 3 / 3 |
| Metric | Q2 2026 | Q3 2026 | Q4 2026 | Q1 2027 | Q2 2027 | Q3 2027 | Q4 2027 |
|---|---|---|---|---|---|---|---|
| Revenue Avg | $135M | $139M | $142M | $141M | $145M | $147M | $149M |
| Low | $134M | $139M | $141M | $140M | $144M | $146M | $148M |
| High | $135M | $140M | $142M | $142M | $145M | $147M | $149M |
| EBITDA Avg | $44M | $46M | $47M | $46M | $48M | $48M | $49M |
| Low | $44M | $46M | $46M | $46M | $47M | $48M | $49M |
| High | $45M | $46M | $47M | $47M | $48M | $48M | $49M |
| EBIT Avg | $39M | $40M | $41M | $40M | $41M | $42M | $43M |
| Low | $38M | $40M | $40M | $40M | $41M | $42M | $42M |
| High | $39M | $40M | $41M | $41M | $42M | $42M | $43M |
| Net Income Avg | $31M | $35M | $39M | $38M | $40M | $40M | $41M |
| Low | $29M | $35M | $38M | $38M | $39M | $40M | $40M |
| High | $33M | $35M | $39M | $38M | $40M | $40M | $41M |
| EPS Avg | $0.81 | $0.92 | $1.01 | $0.99 | $1.03 | $1.04 | $1.06 |
| Low | $0.76 | $0.91 | $1.01 | $0.99 | $1.03 | $1.04 | $1.06 |
| High | $0.85 | $0.92 | $1.02 | $1.00 | $1.04 | $1.05 | $1.07 |
| Analysts (Rev / EPS) | 2 / 3 | 2 / 2 | 1 / 1 | 1 / 1 | 1 / 1 | 1 / 1 | 1 / 1 |